Loading news...
Allspring Global Investments Holdings LLC grew its stake in shares of Core Molding Technologies Inc (NYSEAMERICAN:CMT) by 92.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 134,053 shares of the industrial products company's stock after purchasing an additional 64,338
Core Molding Technologies reported a 20% YoY revenue decline in 3Q25, mainly due to weak trucking demand and Volvo's platform transition. CMT's operating margins held up better than expected despite the revenue drop, but topline recovery remains uncertain amid ongoing trade and macro risks. Management expects new Volvo programs and a trucking demand rebound by late 2026/early 2027, but timing and scale are uncertain.
COLUMBUS, Ohio, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced that management will participate in the 17th Annual Southwest IDEAS Investor Conference at The Westin Irving Convention Center Las Colinas on November 19, 2025.
Core Molding Technologies, Inc. ( CMT ) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST Company Participants David Duvall - President, CEO & Director Eric Palomaki - Chief Operating Officer Alex Panda - Executive VP, Secretary, Treasurer & CFO Conference Call Participants Sandra Martin - Three Part Advisors, LLC Alfred Moore - ROTH Capital Partners, LLC, Research Division William Dezellem - Tieton Capital Management, LLC Presentation Operator Good morning, everyone. Welcome to the Core Molding Technologies Third Quarter 2025 Financial Results Conference Call.
Toronto, Ontario--(Newsfile Corp. - Le 4 novembre/November 2025) - Effective immediately, the following companies
Core Molding Technologies (CMT) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.36 per share a year ago.
Core Molding Technologies (CMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD
COLUMBUS, Ohio, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced that management will participate in the 16th Annual Midwest IDEAS Investor Conference at The InterContinental Chicago Magnificent Mile in Chicago on August 26, 2025.
Core Molding Technologies' 2Q25 results show early signs of cycle moderation, with sequential revenue declines improving and management expecting a potential turnaround by FY26-FY27. The company announced a major new Volvo contract, significant CAPEX plans in Mexico, and an orderly CEO transition set for 2026. Revenue diversification is ongoing, with trucking now only 50% of revenues and $200 million in adjacent market opportunities identified.
Core Molding Technologies (CMT 2.98%), a leading manufacturer of engineered structural plastics and composites, reported results for Q2 FY2025 on August 5, 2025. The headline news: while beating both top- and bottom-line analyst estimates (Q2 2025 adjusted EPS of $0.53 vs.
Core Molding Technologies, Inc. (NYSE:CMT ) Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ET Company Participants Alex J. Panda - Executive VP, Secretary, Treasurer & CFO David L.
Core Molding Technologies (CMT) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.73 per share a year ago.
CEO Dave Duvall to Retire May 2026, COO Eric Palomaki to Succeed Duvall CEO Dave Duvall to Retire May 2026, COO Eric Palomaki to Succeed Duvall
COLUMBUS, Ohio, July 17, 2025 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, utilities, transportation and powersports industries across North America, today announces that it will release its second quarter fiscal 2025 results on Tuesday, August 5, 2025, before the market opens. In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the internet the same day at 10:00am Eastern.
WASHINGTON , June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). VCA-894A is being developed for a patient who was first diagnosed at the age of 5 with a rare subtype of CMT disease known as CMT2S.1 CMT2S is an inherited neuromuscular disorder that progressively leads to muscle weakness and loss of motor function, and has an estimated prevalence of less than 1 in 1,000,000 worldwide.2 The severity and clinical presentations of CMT2S are influenced by the diverse genetic variants associated with CMT disease.
COLUMBUS, Ohio, June 05, 2025 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced that management will participate in the 15th Annual East Coast IDEAS Investor Conference at The Westin Time Square in New York City on June 11, 2025.
BCC, DOOO and CMT have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2025.
COLUMBUS, Ohio, May 22, 2025 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced the release of its third annual Sustainability Report, which highlights the Company's ongoing commitment to responsible business practices, community engagement, and environmental stewardship.
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in CMT-SORD-Null rats demonstrated a highly statistically significant 37% (p=0.005) reduction of sorbitol in the sciatic nerve, the tissue of interest, after treatment with govorestat.Reflective of the peripheral neuropathy experienced by patients with CMT-SORD. Govorestat remains generally safe and well tolerated Company remains committed to potential NDA submission of govorestat for treatment of CMT-SORD in 2025 NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare disease, today presented full 12-month clinical results and new topline data from 18 and 24 months from the INSPIRE Phase 2/3 trial of govorestat (AT-007) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease, in an oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20, 2025 in Edinburgh, Scotland.